Incretin Therapies: Effects Beyond Glycemic Control

American Journal of Medicine

Volumn 122, Issue 6 SUPPL., 2009, Pages

  Mudaliar, Sunder ^a,b   Henry, Robert R ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

DDP 4 inhibitors; extra glycemic effects; GLP 1 receptor agonists

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FATTY ACID; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PARACETAMOL; SITAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CELL FUNCTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DEGENERATIVE DISEASE; DIET RESTRICTION; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEART FUNCTION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MORNING DOSAGE; NAUSEA; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; STOMACH EMPTYING; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; PROGNOSIS; REVIEW; SECRETION;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; PROGNOSIS;

EID: 67049118921     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.03.014     Document Type: Article

References (74)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
2. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes. A progressive disease. Diabetes 44 (1995) 1249-1258
3. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
4. Brubaker P.L., and Drucker D.J. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145 (2004) 2653-2659
5. Fehse F., Trautmann M., Holst J.J., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 5991-5997
6. Chang A.M., Jakobsen G., Sturis J., et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52 (2003) 1786-1791
7. Vilsbøll T., Brock B., Perrild H., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic β-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 25 (2008) 152-156
8. Xu L., Man C.D., Charbonnel B., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 10 (2008) 1212-1220
9. Mari A., Sallas W.M., He Y.L., et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 4888-4894
10. D'Alessio D.A., Denney A.M., Hermiller L.M., et al. Treatment with the DPP-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 94 (2009) 81-88
11. Utzschneider K.M., Tong J., Montgomery B., et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31 (2008) 108-113
12. A randomized, controlled trial comparing the effect of exenatide, sitagliptin or glimepiride on functional β-cell mass in patients with impaired fasting glucose or early type 2 diabetes. [ClinicalTrials.gov Website.]. http://www.clinicaltrials.gov Accessed December 29, 2008. ClinicalTrials.gov identifier NCT00775684
13. A randomized controlled pilot study assessing the effect of sitagliptin on the preservation of beta-cell function in patients with type 2 diabetes: preservation of beta-cell function measured by area-under-the-curve (C-peptide/glucose)/HOMA-IR. http://clinicaltrials.gov/ct2/show/NCT00420511?spons=%22Samuel+Lunenfeld+Research+Institute%2C+Mount+Sinai+Hospital%22&spons_ex=Y&rank=1 Accessed December 29, 2008. Clinical Trials.gov identifier NCT00420511
14. Gedulin B.R., Nikoulina S.E., Smith P.A., et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146 (2005) 2069-2076
15. Gutniak M., Orskov C., Holst J.J., Ahrén B., and Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326 (1992) 1316-1322
16. Meneilly G.S., McIntosh C.H., Pederson R.A., et al. Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care 26 (2003) 837-842
17. D'Alessio D.A., Kahn S.E., Leaner C.R., and Ensigncy J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93 (1994) 2263-2266
18. Vella A., Shah P., Reed A.S., Adkins A.S., Basu R., and Rizza R.A. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45 (2002) 1410-1415
19. Vella A., Shah P., Basu R., Basu A., Holst J.J., and Rizza R.A. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49 (2000) 611-617
20. Vilsbøll T., Zdravkovic M., Le Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30 (2007) 1608-1610
21. Meneilly G.S., McIntosh C.H., Pederson R.A., et al. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24 (2001) 1951-1956
22. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
23. Naslund E., Barkeling B., King N., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23 (1999) 304-311
24. Gutzwiller J.P., Drewe J., Goke B., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol Regul Integr Comp Physiol 276 (1999) R1541-R1544
25. Wang G.J., Tomasi D., Backus W., et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage 39 (2008) 1824-1831
26. Nakabayashi H., Nishizawa M., Nakagawa A., Takeda R., and Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271 (1996) E808-E813
27. Tang-Christensen M., Larsen P.J., Göke R., et al. Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats. Am J Physiol 271 (1996) R848-R856
28. Kastin A.J., Akerstrom V., and Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18 (2002) 7-14
29. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., and MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24 (2008) 2943-2952
30. Harder H., Nielsen L., Tu D.T., and Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27 (2004) 1915-1921
31. Degn K.B., Juhl C.B., Sturis J., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53 (2004) 1187-1194
32. Nauck M., Frid A., Hermansen K., et al., LEAD-2 Metformin Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 32 (2009) 84-90
33. Garber A., Henry R., Ratner R., et al., LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009) 473-481
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
35. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
36. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., and Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways [published correction appears in Circulation. 2008;118:e81]. Circulation 117 (2008) 2340-2350
37. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
38. Sokos G.G., Bolukoglu H., German J., et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100 (2007) 824-829
39. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., and Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006) 694-699
40. Noyan-Ashraf M.H., Momen M.A., Ban K., et al. The GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes 58 (2009) 975-983
41. The effect of exenatide compared to insulin glargine on cardiac function and metabolism in type 2 diabetic patients with congestive heart failure (NYHA II): a randomized comparator-controlled trial. [ClinicalTrials.gov Website.]. http://clinicaltrials.gov/ct2/show/NCT00766857?term=exenatide+AND+myocardial&rank=2 Accessed December 29, 2008. Clinical Trials.gov identifier NCT00766857
42. Nyström T., Gutniak M.K., Zhang Q., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287 (2004) E1209-E1215
43. The effect of liraglutide on endothelial function in subjects with type 2 diabetes mellitus. [ClinicalTrials.gov Website.]. http://www.clinicaltrials.gov Accessed December 29, 2008. ClinicalTrials.gov identifier NCT00620282
44. Yamamoto H., Lee C.E., Marcus J.N., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 (2002) 43-52
45. Barragan J.M., Rodriguez R.E., and Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol Endocrinol Metab 266 (1994) E459-E466
46. Yu M., Moreno C., Hoagland K.M., et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21 (2003) 1125-1135
47. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
48. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
49. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
50. Moretto T.J., Milton D.R., Ridge T.D., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30 (2008) 1448-1460
51. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24 (2008) 275-286
52. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care (2009) Mar 16. [Epub ahead of print]
53. Mistry G.C., Maes A.L., Lasseter K.C., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 48 (2008) 592-598
54. The effect of sitagliptin on hypertension, arterial stiffness, oxidative stress and inflammation. [ClinicalTrials.gov Website.]. http://www.clinicaltrials.gov Accessed December 29, 2008. ClinicalTrias.gov identifier NCT00696982
55. Meier J.J., Gethmann A., Götze O., et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49 (2006) 452-458
56. Cervera A., Wajcberg E., Sriwijitkamol A., et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 294 (2008) E846-E852
57. Blonde L., Klein E.J., Han J., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 (2006) 436-447
58. Matikainen N., Mänttäri S., Schweizer A., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49 (2006) 2049-2057
59. A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of sitagliptin on postprandial plasma lipoprotein concentrations in men with type 2 diabetes. [ClinicalTrials.gov Website.]. http://www.clinicaltrials.gov Accessed December 29, 2008. ClinicalTrials.gov identifier NCT00660075
60. Rosenstock J., Brazg R., Andryuk P.J., Lu K., Stein P., and Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28 (2006) 1556-1568
61. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007) 1409-1439
62. Alvarez E., Martinez M.D., Roncero I., et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92 (2005) 798-806
63. Körner M., Stöckli M., Waser B., and Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48 (2007) 736-743
64. D'Alessio D.A., Sandoval D.A., and Seeley R.J. New ways in which GLP-1 can regulate glucose homeostasis. J Clin Invest 115 (2005) 3406-3408
65. Sandoval D.A., Bagnol D., Woods S.C., D'Alessio D.A., and Seeley R.J. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57 (2008) 2046-2054
66. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 277 pt 2 (1999) R582-R590
67. During M.J., Cao L., Zuzga D.S., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9 (2003) 1173-1179
68. Perry T., Haughey N.J., Mattson M.P., Egan J.M., and Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302 (2002) 881-888
69. Imeryüz N., Yeǧen B.C., Bozkurt A., Coşkun T., Villanueva-Peñacarrillo M.L., and Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273 pt 1 (1997) G920-G927
70. Rogers R.C., McTigue D.M., and Hermann G.E. Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci Biobehav Rev 20 (1996) 57-66
71. Bertilsson G., Patrone C., Zachrisson O., et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. Neurosci Res 86 (2008) 326-338
72. Lerche S., Brock B., Rungby J., et al. Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes 57 (2008) 325-331
73. The effect of the GLP-1 analogue exenatide on type 2 diabetes in CNS and heart during hyperglycemia assessed by PET. [ClinicalTrials.gov Website.]. http://www.clinicaltrials.gov Accessed December 29, 2008. ClinicalTrials.gov identifier NCT00747968
74. Yamada C., Yamada Y., Tsukiyama K., et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149 (2008) 574-579